Decreased monocyte activation with daily acyclovir use in HIV-1/HSV-2 coinfected women

Sexually Transmitted Infections

Volumn 91, Issue 7, 2015, Pages 485-488

  Redd, Andrew D ^a,b   Newell, Kevin ^c   Patel, Eshan U ^a   Nalugoda, Fred ^d   Ssebbowa, Paschal ^d   Kalibbala, Sarah ^d   Frank, Melanie A ^a   Tobian, Aaron A R ^b   Gray, Ronald H ^e   Quinn, Thomas C ^a,b   Serwadda, David ^d,f   Reynolds, Steven J ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^d RAKAI HEALTH SCIENCES PROGRAM   (Uganda)

^e JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^f MAKERERE UNIVERSITY   (Uganda)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; C REACTIVE PROTEIN; CD14 ANTIGEN; PLACEBO; ANTIVIRUS AGENT;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; CELL ACTIVATION; CONTROLLED STUDY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 2; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MIDDLE AGED; MIXED INFECTION; MONOCYTE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VIRUS LOAD; BLOOD; CHEMISTRY; COMPLICATION; HERPES GENITALIS; HIV INFECTIONS; IMMUNOLOGY; ISOLATION AND PURIFICATION; YOUNG ADULT;

ACYCLOVIR; ADULT; ANTIGENS, CD14; ANTIVIRAL AGENTS; C-REACTIVE PROTEIN; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HERPES GENITALIS; HERPESVIRUS 2, HUMAN; HIV INFECTIONS; HIV-1; HUMANS; MIDDLE AGED; MONOCYTES; YOUNG ADULT;

EID: 84945539306     PISSN: 13684973     EISSN: 14723263     Source Type: Journal    
DOI: 10.1136/sextrans-2014-051867     Document Type: Article

References (14)

1. Moriuchi M, Moriuchi H, Williams R, et al. Herpes simplex virus infection induces replication of human immunodeficiency virus type 1. Virology 2000;278:534-40.
2. Tobian AA, Quinn TC. Herpes simplex virus type and syphilis infections with HIV: an evolving synergy in transmission and prevention. Curr Opin HIV AIDS 2009;4:294-9.
3. Reynolds SJ, Makumbi F, Newell K, et al. Effect of daily acyclovir on HIV disease progression in individuals in Rakai, Uganda, co-infected with HIV-1 and herpes simplex virus type 2: a randomised, double-blind placebo-controlled trial. Lancet Infect Dis 2012;12:441-8.
4. Lingappa JR, Baeten JM, Wald A, et al. Daily acyclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial. Lancet 2010;375:824-33.
5. Celum C, Wald A, Lingappa JR, et al. Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. N Engl J Med 2010;362:427-39.
6. Baeten JM, Reid SE, Delany-Moretlwe S, et al. Clinical and virologic response to episodic acyclovir for genital ulcers among HIV-1 seronegative, herpes simplex virus type 2 seropositive African women: a randomized, placebo-controlled trial. Sex Transm Dis 2012;39:21-4.
7. Mugwanya K, Baeten JM, Mugo NR, et al. High-dose valacyclovir HSV-2 suppression results in greater reduction in plasma HIV-1 levels compared with standard dose acyclovir among HIV-1/HSV-2 c oinfected persons: a randomized, crossover trial. J Infect Dis 2011;204:1912-17.
8. McMahon MA, Siliciano JD, Lai J, et al. The antiherpetic drug acyclovir inhibits HIV replication and selects the V75I reverse transcriptase multidrug resistance mutation. J Biol Chem 2008;283:31289-93.
9. McMahon MA, Parsons TL, Shen L, et al. Consistent inhibition of HIV-1 replication in CD4+ T cells by acyclovir without detection of human herpesviruses. J Virol 2011;85:4618-22.
10. Yi TJ, Walmsley S, Szadkowski L, et al. A randomized controlled pilot trial of valacyclovir for attenuating inflammation and immune activation in HIV/herpes simplex virus 2-coinfected adults on suppressive antiretroviral ther apy. Clin Infect Dis 2013;57:1331-8.
11. Yi TJ, Shannon B, Chieza L, et al. Valacyclovir Therapy Does Not Reverse Herpes-Associated Alterations in Cervical Immunology: A Randomized, Placebo-Controlled C rossover Trial. J Infect Dis 2014;210:708-12.
12. Redd AD, Eaton KP, Kong X, et al. C-reactive protein levels increase during HIV-1 disease progression in Rakai, Uganda, despite the absence of mi crobial translocation. J Acquir Immune Defic Syndr 2010;54:556-9.
13. Sandler NG, Wand H, Roque A, et al. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis 2011;203:780-90.
14. Redd AD, Wendel SK, Grabowski MK, et al. Liver stiffness is associated with monocyte activation in HIV-infected Ugandans without viral hepatitis. AIDS Res Hum Retrov iruses 2013;29:1026-30.